Why did SNPX's EPS remain flat in recent quarters?

The EPS of Synaptogenix (SNPX) has remained flat in recent quarters due to a combination of factors: 1. **Revenue and Net Margin**: Synaptogenix's revenue and net margin have not been provided for the recent quarters, which makes it difficult to analyze the company's profitability and its impact on the EPS. 2. **Operating Expenses and Losses**: The company's operating expenses and losses have been significant, with net losses reported in the range of $1.36 million to $6.05 million for the quarters ending September 30, 2024, and December 31, 2023. These losses could be a result of the company's ongoing research and development expenses, general and administrative expenses, and strategic investments. 3. **Investment in Research and Development**: Synaptogenix has been actively investing in research and development, with significant expenses incurred for the development of Bryostatin-1 and other projects. These investments are likely impacting the company's short-term profitability, which in turn affects the EPS. 4. **Strategic Partnerships and Investments**: The company has increased its stake in innovative psilocybin drug discovery company PsygaBio through its partnership with Cannasoul Analytics. These strategic moves may require significant investments, which could impact the company's financial performance in the short term. In conclusion, Synaptogenix's EPS has remained flat in recent quarters due to a combination of factors including lack of revenue, significant operating expenses, investment in research and development, and strategic partnerships.